Should you buy Beam Therapeutics stock now?
The technical signal for Beam Therapeutics is currently Hold. Beam Therapeutics trades at $25.87 as of Nov 6, 2026. The technical analysis shows the following: MACD is positive (bullish trend) at 0.440 with rising momentum (signal: 0.233); RSI is at 50.4 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $49.38 points to 90.9% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Beam Therapeutics stock?
The average analyst price target for Beam Therapeutics is $49.38. The current price is $25.87, which gives an upside of 90.9%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $44.44 and $54.32.
Is Beam Therapeutics a dividend stock?
No, Beam Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Beam Therapeutics stock?
Beam Therapeutics is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 72.1%, which classifies the stock as Extremely speculative.
Is Beam Therapeutics overvalued?
No, Beam Therapeutics is considered undervalued based on the analyst price target (90.9% upside). Beam Therapeutics has the following valuation ratios: a P/S ratio of 19.6, a P/B ratio of 2.6. The analyst price target suggests that the stock is undervalued by 90.9%.
Is Beam Therapeutics overbought?
No, Beam Therapeutics is not overbought. RSI is at 50.4 (neutral zone). The technical indicators show: RSI is at 50.4 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 1.6% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Beam Therapeutics earnings report?
The date of the next earnings report for Beam Therapeutics has not been published yet. Check the company's investor calendar for updates.
Is Beam Therapeutics shorted?
Yes, Beam Therapeutics is shorted with 39.2% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Beam Therapeutics stock?
No, insiders are not buying Beam Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 3 sales. On a net basis, 1,193,315 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 17,879,184 $ sold. Active sellers include Evans John M., Cavanagh Bethany J, Simon Amy and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Beam Therapeutics a good stock?
Based on our total score, Beam Therapeutics is rated as a disastrous stock with a total score of 18 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 15/100, Momentum: 39/100. In addition: analysts see 90.9% upside to the price target. Whether now is the time to buy is a separate question: the technical signal is Hold. Whether Beam Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Beam Therapeutics stock?
The outlook for Beam Therapeutics based on current data: the average analyst price target is $49.38 (+90.9%). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Beam Therapeutics stock moving?
Beam Therapeutics is stable right now. The technical indicators show: the price is close to the 20-day average; MACD is positive with rising momentum (bullish signal); short interest is 39.2% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Beam Therapeutics go?
The average analyst price target for Beam Therapeutics is $49.38, which corresponds to a potential gain of 90.9% from the current price of $25.87. The stock has traded between $20.23 and $38.26 over the last 52 weeks. The price is 32.4% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Beam Therapeutics fall?
The stock has traded as low as $20.23 over the last 52 weeks — that is 21.8% below the current price of $25.87. The biggest decline (drawdown) in the same period was 47.1% from high to low. Within a year, the price typically swings about ±72.1% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Beam Therapeutics do?
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-s... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Beam Therapeutics as an investment.
Did Beam Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Beam Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Beam Therapeutics making money or losing money?
No, Beam Therapeutics is currently not making money — the company is losing money with a negative profit margin of -73.9%, a substantial loss. That means the business loses money on every dollar of revenue. The operating margin (profit before interest and taxes) is also negative at -46,033.2% — so it is not just financing costs weighing on the result. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Beam Therapeutics go bankrupt?
The bankruptcy risk of Beam Therapeutics is rated as moderate. Altman Z2 (a model for assessing financial distress) is 2.57 — that places the company in the middle zone. The Piotroski score (financial health 0-9, higher is better) is 4 — which is average. Debt relative to equity is 50% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Beam Therapeutics have a lot of debt?
No, Beam Therapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 50%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.